In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

Over-the-counter and home remedies typically treat it. Severe rashes that do not respond to basic care or last more than a few days may be due to an infection or underlying medical condition.

Like other symptoms, itchy skin and rashes may not appear in the early stages of kidney disease. Instead, they may appear when the minerals in the blood become unbalanced due to the kidney’s ...

Acitretin: This medication is an oral (take by mouth) retinoid that can clear or markedly reduce widespread rashes, bumps, and other signs on your skin. Retinoids should not be used during pregnancy, ...

Phase 3 trial shows promising pain relief for acute pain patients Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol for treating ...

Skin types are typically categorized as normal, oily, dry, combination, or sensitive. Knowing your skin type can help you choose the ideal products for your needs, maintain healthy skin, and reduce ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT (amivantamab) for the first-line treatment of adult patients with advanced ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...